PsychonautWiki Archive

Talk:MMDA: Difference between revisions

← Older edit
>Dextromethorphan
edit efdects
>Yzgzs
→Chemistry: Added content
 
(38 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{headerpanel|{{approval}}}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/MMDA}}
{{SubstanceBox/MMDA}}
Line 8: Line 9:
Shulgin noted that he had synthesized MMDA in 1962 while simultaneously Dr. Gordon A also synthesized MMDA in 1962 and named it accordingly.<ref>https://erowid.org/library/books_online/pihkal/pihkal132.shtml</ref>
Shulgin noted that he had synthesized MMDA in 1962 while simultaneously Dr. Gordon A also synthesized MMDA in 1962 and named it accordingly.<ref>https://erowid.org/library/books_online/pihkal/pihkal132.shtml</ref>


It is strongly advised to use [[harm reduction]] practises when using this drug.
It is strongly advised to use [[harm reduction]] practises when choosing to use this drug.


==Chemistry==
==Chemistry==
Line 14: Line 15:
MMDA, also known as 5-methoxy-3,4-methylenedioxyamphetamine, is a synthetic molecule of the [[Substituted amphetamine|substituted amphetamine]] family. Molecules of the amphetamine class contain a [[phenethylamine]] core featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain with an additional methyl substitution at R<sub>α</sub>. Additionally, MMDA contains substitutions at R<sub>3</sub> and R<sub>4</sub> of the phenyl ring with oxygen groups that are incorporated into a methylenedioxy ring through a methylene bridge. In addition, it contains a methoxy group at R<sub>5</sub>. MMDA shares this methylenedioxy ring with other drugs like [[MDA]] and [[MDMA]] but differs with its additional methoxy substitution.
MMDA, also known as 5-methoxy-3,4-methylenedioxyamphetamine, is a synthetic molecule of the [[Substituted amphetamine|substituted amphetamine]] family. Molecules of the amphetamine class contain a [[phenethylamine]] core featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain with an additional methyl substitution at R<sub>α</sub>. Additionally, MMDA contains substitutions at R<sub>3</sub> and R<sub>4</sub> of the phenyl ring with oxygen groups that are incorporated into a methylenedioxy ring through a methylene bridge. In addition, it contains a methoxy group at R<sub>5</sub>. MMDA shares this methylenedioxy ring with other drugs like [[MDA]] and [[MDMA]] but differs with its additional methoxy substitution.


It is chemically related to its [[precursor]] compound, [[myristicin]].
It is chemically related to its [[precursor]] compound, [[myristicin]]. It is believed that MMDA plays a role in the effects and pharmacology of myristicin.<ref>https://erowid.org/library/books_online/pihkal/pihkal132.shtml</ref>


==Pharmacology==
==Pharmacology==
Line 21: Line 22:


It is also theorized to act as a 5-HT<sub>2</sub>A receptor agonist. However, how the [[psychedelic]] and [[hallucinogenic]] effects work is currently not entirely known.
It is also theorized to act as a 5-HT<sub>2</sub>A receptor agonist. However, how the [[psychedelic]] and [[hallucinogenic]] effects work is currently not entirely known.
[[Alexander Shulgin]] notes that MMDA is responsible for some of the effects of [[myristicin]].<ref>https://erowid.org/library/books_online/pihkal/pihkal132.shtml</ref>


==Subjective effects==
==Subjective effects==
{{effectStub}}
{{effectStub}}
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
===Physical effects===
{{effects/base
|{{effects/physical|
*'''[[Effect::Spontaneous tactile sensations]]''' - The "body high" of MMDA can be characterized as a moderate to extreme euphoric relaxing sensation that encompasses the entire body. It is capable of becoming overwhelmingly pleasurable at higher doses to the point of "flooring" or immobilizing the user. This sensation maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Spontaneous tactile sensations]]''' - The "body high" of MMDA can be characterized as a moderate to extreme euphoric relaxing sensation that encompasses the entire body. It is capable of becoming overwhelmingly pleasurable at higher doses to the point of "flooring" or immobilizing the user. This sensation maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Stimulation]]'''<!-- - In terms of its effects on the user's physical energy levels, MMDA is commonly regarded as significantly less stimulating and energizing than MDMA, unlike MDMA, which encourages activities such as running, climbing and dancing in a way that makes it a popular choice for musical events such as festivals and raves. The distinct style of stimulation which MMDA presents can be described as mildly to moderately forced, trending more towards sedation and relaxation. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily body shakes and vibrations become present, resulting in an extreme unsteadiness of the hands and a general lack of motor control, though to a far lesser degree than with MDMA. -->
*'''[[Effect::Stimulation]]'''<!-- - In terms of its effects on the user's physical energy levels, MMDA is commonly regarded as significantly less stimulating and energizing than MDMA, unlike MDMA, which encourages activities such as running, climbing and dancing in a way that makes it a popular choice for musical events such as festivals and raves. The distinct style of stimulation which MMDA presents can be described as mildly to moderately forced, trending more towards sedation and relaxation. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily body shakes and vibrations become present, resulting in an extreme unsteadiness of the hands and a general lack of motor control, though to a far lesser degree than with MDMA. -->
Line 39: Line 43:
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Perception of decreased weight]]'''
*'''[[Effect::Perception of decreased weight]]'''
*'''[[Effect::Physical euphoria]]''' - This effect is not as reliably induced with substances such as [[MDMA]]
*'''[[Effect::Physical euphoria]]''' - This effect is not as reliably induced with substances such as [[MDMA]] or [[MDA]] and higher dosages may result in physical dysphoria.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Stamina enhancement]]'''
*'''[[Effect::Stamina enhancement]]'''
*'''[[Effect::Tactile enhancement]]'''
*'''[[Effect::Tactile enhancement]]'''
*'''[[Effect::Teeth grinding]]''' - This component is usually only present in the higher dose range, and to a lesser extent than the teeth grinding associated with MDMA.  
*'''[[Effect::Teeth grinding]]''' - This is a typical effect of [[entactogens]] such as MDMA and MDA.
*'''[[Effect::Temporary erectile dysfunction]]'''
*'''[[Effect::Temporary erectile dysfunction]]'''
}}


===Cognitive effects===
{{effects/visual|
The cognitive effects of MDEA can be broken down into several components which progressively intensify proportional to dosage. The broad head space of MDEA is described by many as one of moderate mental stimulation, feelings of love, warmth or empathy and powerful relaxing euphoria. It contains a large number of typical [[Psychedelics|psychedelic]], [[Entactogens|entactogenic]] and [[Stimulants|stimulant]] cognitive effects.


The most prominent of these cognitive effects generally include:
MMDA has pronounced imagery within its closed-eye visuals with scenes and stories.
 
*'''[[Effect::Cognitive euphoria]]''' - Strong emotional euphoria and feelings of happiness are present within MDEA and are likely a direct result of serotonin and dopamine release.
*'''[[Effect::Empathy, love, and sociability enhancement]]''' - This particular effect is present, but not nearly as consistent, pronounced, powerful and therapeutic than one would experience with MDMA With time and repeated use, however, this effect becomes severely diminished as the perspective it instills becomes fully grounded and already in place, making people feel merely stimulated and euphoric with no new found urges to communicate, with others. Some users report that MDEA "loses its magic" with as few as 10 experiences, while others have reported hundreds of uses before the empathic qualities disappear. This does not appear to be valid for all users, however, with many users reporting that they have not experienced any decrease in quality of the experience despite dozens or even hundreds of uses.
*'''[[Effect::Time distortion]]''' - Strong feelings of time compression are common within MDEA and speed up the experience of time quite noticeably.
*'''[[Effect::Unity and interconnectedness]]''' - Experiences of unity, oneness and interconnectedness between level 1 - 2 are common within MDEA.
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Compulsive redosing]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Dream suppression]]'''
*'''[[Effect::Existential self-realization]]''' - Although this effect is present, it is not quite as pronounced or as consistent when compared to other [[hallucinogen]]s such as [[mescaline]], [[Psilocin]], [[LSD]] or [[MXE]] or even other entactogens like MDMA.
*'''[[Effect::Focus enhancement]]''' - This component is most effective at low to moderate doses as anything higher will usually impair concentration.
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Increased libido]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Mindfulness]]'''
*'''[[Effect::Motivation enhancement]]'''
*'''[[Effect::Thought acceleration]]'''
 
===Visual effects===


====Enhancements====
====Enhancements====
MDEA presents an array of visual enhancements which are mild in comparison to traditional psychedelics, but still distinctively present. These generally include:
MMDA presents an array of visual enhancements which at appropriately high doses produce a full spectrum of open-eye and closed-eye visuals. These generally include:
*'''[[Effect::Colour enhancement]]'''
*'''[[Effect::Colour enhancement]]'''  
*'''[[Effect::Pattern recognition enhancement]]'''
*'''[[Effect::Pattern recognition enhancement]]'''


Line 83: Line 68:


====Hallucinatory states====
====Hallucinatory states====
MDEA is capable of producing a unique range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used [[psychedelic]]s. These effects are far more common during the [[Duration#Offset|offset]] of the experience and commonly include:
MMDA is capable of producing a unique range of high level hallucinatory states in a fashion that is significantly more consistent and reproducible than that other [[entactogens]] but less that of many other commonly used [[psychedelic]]s. These effects are consistent at high dosages and commonly include:
*'''[[Effect::Peripheral information misinterpretation]]
*'''[[Effect::Peripheral information misinterpretation]]
*'''[[Effect::Internal hallucination]]'''
}}
|{{effects/cognitive|
The cognitive effects of MMDA can be broken down into several components which progressively intensify proportional to dosage. It contains a large number of typical [[Psychedelics|psychedelic]], [[Entactogens|entactogenic]] and [[Stimulants|stimulant]] cognitive effects.
MMDA's headspace at lower dosages is relaxing with feelings of euphoria and happiness. Higher dosages however result in increasingly deep and vivid "dreams" reminiscent of distinct hallucinogenic and [[deliriant]] effects.
The most prominent of these cognitive effects generally include:


===Auditory effects===
*'''[[Effect::Cognitive euphoria]]''' - At low to common dosages, strong emotional euphoria and feelings of happiness are present within MMDA and are likely a direct result of serotonin and dopamine release. At higher dosages, the [[deliriant]] effects typically result in cognitive dysphoria.
*'''[[Effect::Empathy, love, and sociability enhancement]]''' - This particular effect is present, but not nearly as consistent, pronounced, powerful and therapeutic than one would experience with [[MDMA]] With time and repeated use, however, this effect becomes severely diminished as the perspective it instills becomes fully grounded and already in place, making people feel merely stimulated and euphoric with no new found urges to communicate, with others. Some users report that MMDA "loses its magic" with as few as 10 experiences, while others have reported hundreds of uses before the empathic qualities disappear. This does not appear to be valid for all users, however, with many users reporting that they have not experienced any decrease in quality of the experience despite dozens or even hundreds of uses.
*'''[[Effect::Time distortion]]'''
*'''[[Effect::Unity and interconnectedness]]''' <!-- Experiences of unity, oneness and interconnectedness between level 1 - 2 are common within MMDA. -->
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Compulsive redosing]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Dream suppression]]'''
*'''[[Effect::Existential self-realization]]''' <!-- - Although this effect is present, it is not quite as pronounced or as consistent when compared to other [[hallucinogen]]s such as [[mescaline]], [[Psilocin]], [[LSD]] or [[MXE]] or even other entactogens like MDMA. -->
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Increased libido]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Mindfulness]]'''
*'''[[Effect::Motivation enhancement]]'''
*'''[[Effect::Thought acceleration]]'''
}}
 
{{effects/auditory|
*'''[[Effect::Auditory enhancement|Enhancements]]'''
*'''[[Effect::Auditory enhancement|Enhancements]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
}}


===After effects===
{{effects/aftereffects|
The effects which occur during the [[offset]] of a [[stimulant]] experience generally feel negative and uncomfortable in comparison to the effects which occurred during its [[peak]]. This is often referred to as a "comedown" and occurs because of [[neurotransmitter]] depletion. Its effects commonly include:
The effects which occur during the [[offset]] of a [[stimulant]] experience generally feel negative and uncomfortable in comparison to the effects which occurred during its [[peak]]. This is often referred to as a "comedown" and occurs because of [[neurotransmitter]] depletion. Its effects commonly include:
*'''[[Effect::Anxiety]]'''
*'''[[Effect::Anxiety]]'''
Line 97: Line 109:
*'''[[Effect::Cognitive fatigue]]'''
*'''[[Effect::Cognitive fatigue]]'''
*'''[[Effect::Depression]]'''
*'''[[Effect::Depression]]'''
*'''[[Effect::Dream potentiation]]''' - Some users note extremely strange, vivid and sometimes rather scary dreams for several nights after taking large doses of MDEA.
*'''[[Effect::Dream potentiation]]''' - Some users note extremely strange, vivid and sometimes rather scary dreams for several nights after taking large doses of MMDA.
*'''[[Sleep paralysis]]''' - Some users note sleep paralysis after consuming MDEA, particularly in high doses or in conjunction with other factors such as lack of sleep or physical fatigue.
*'''[[Sleep paralysis]]''' - Some users note sleep paralysis after consuming MMDA, particularly in high doses or in conjunction with other factors such as lack of sleep or physical fatigue.
*'''[[Effect::Irritability]]'''
*'''[[Effect::Irritability]]'''
*'''[[Effect::Motivation suppression]]'''
*'''[[Effect::Motivation suppression]]'''
*'''[[Effect::Thought deceleration]]'''  
*'''[[Effect::Thought deceleration]]'''  
*'''[[Effect::Wakefulness]]'''
*'''[[Effect::Wakefulness]]'''
}}
}}
===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
There are currently {{#ask: [[Category:MMDA]][[Category:Experience]]|format=ul|Columns=1}} anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
* [https://erowid.org/experiences/subs/exp_MDE.shtml Erowid Experience Vaults: MDEA]
* [https://erowid.org/experiences/subs/exp_MMDA.shtml Erowid Experience Vaults: MMDA]


==Toxicity and harm potential==
==Toxicity and harm potential==
===Short-term health concerns===
===Short-term health concerns===
Short-term physical health risks of MDEA consumption include [[dehydration]], [[insomnia]], [[hyperthermia]],<ref>Drug-induced hyperthermia | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.1993.tb07423.x/abstract;jsessionid=FC30A9B157A2BAFC81048D8595714565.f02t03</ref><ref>Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9634574</ref> and hyponatremia.<ref>Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population | http://jop.sagepub.com/content/20/3/400</ref> Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.
Short-term physical health risks of MMDA consumption include [[dehydration]], [[insomnia]], [[hyperthermia]],<ref>Drug-induced hyperthermia | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.1993.tb07423.x/abstract;jsessionid=FC30A9B157A2BAFC81048D8595714565.f02t03</ref><ref>Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9634574</ref> and hyponatremia.<ref>Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population | http://jop.sagepub.com/content/20/3/400</ref> Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.


The [[Toxicity::exact toxic dosage is unknown]], but considered to be far greater than its active dose.
The [[Toxicity::exact toxic dosage is unknown]]. It is advised to avoid very large doses of this compound.


===Long-term health concerns===
===Long-term health concerns===
As with MDMA, the neurotoxicity of MDEA use has long been the subject of debate. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MDEA is most certainly neurotoxic in some form.
The neurotoxicity of MMDA is currently not known, but it can be assumed to posess a similar or greater neurotoxicity than [[MDMA]] and more compareable to [[MDA]]. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MMDA is most likely neurotoxic in some form.
 
Like other powerful serotonin releasing agents, MMDA is thought to cause down-regulation of [[serotonin]] reuptake transporters in the brain. The rate at which the brain recovers from serotonergic changes is unclear. One study demonstrated lasting serotonergic changes in some animals exposed to MDMA, which likely applies to MMDA as well.<ref>Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/7643196</ref>
 
<!--
Other studies have suggested that the brain may recover from serotonergic damage.<ref>In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9593108</ref><ref>Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001). "Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings". Arch. Gen. Psychiatry 58 (10): 901–6. </ref><ref>Selvaraj, S. et al (2009) "Brain Serotonin transporter binding in former users of MDMA ("ecstasy")." British Journal of Psychiatry. 194: 355-359. | https://www.ncbi.nlm.nih.gov/pubmed/19336788</ref>


Like other powerful serotonin releasing agents, MDEA is thought to cause down-regulation of [[serotonin]] reuptake transporters in the brain. The rate at which the brain recovers from serotonergic changes is unclear. One study demonstrated lasting serotonergic changes in some animals exposed to MDMA, which likely applies to MDEA as well.<ref>Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDEA, "ecstasy") (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/7643196</ref> Other studies have suggested that the brain may recover from serotonergic damage.<ref>In vivo detection of short- and long-term MDEA neurotoxicity--a positron emission tomography study in the living baboon brain (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9593108</ref><ref>Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001). "Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDEA or "ecstasy"): preliminary findings". Arch. Gen. Psychiatry 58 (10): 901–6. </ref><ref>Selvaraj, S. et al (2009) "Brain Serotonin transporter binding in former users of MDEA ("ecstasy")." British Journal of Psychiatry. 194: 355-359. | https://www.ncbi.nlm.nih.gov/pubmed/19336788</ref>
-->


Like with MDMA, the long-term heavy use of MDEA is likely similarly cardiotoxic, leading to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref> In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years, mean of age 24.3 years) had developed clinically evident valvular heart disease.<ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>
Like with MDMA, the long-term heavy use of MMDA is likely similarly or even more cardiotoxic, leading to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref> In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years, mean of age 24.3 years) had developed clinically evident valvular heart disease.<ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.


===Tolerance and addiction potential===
===Tolerance and addiction potential===
As with other [[stimulant]]s, the chronic use of MDEA can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage.
As with other [[stimulant]]s, the chronic use of MMDA can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage.


Tolerance to many of the effects of MDEA develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly larger doses to achieve the same effects. After that, it takes about [[Time to half tolerance::1 months]] for the tolerance to be reduced to half and [[Time to zero tolerance::2-3 months]] to be back at baseline (in the absence of further consumption). MDEA presents cross-tolerance with [[Cross-tolerance::all [[dopamine]]rgic and [[serotonin|serotonergic]] [[stimulant]]s and entactogens]], meaning that after the consumption of MDEA all of these will have a reduced effect.
Tolerance to many of the effects of MMDA develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly larger doses to achieve the same effects. After that, it takes about [[Time to half tolerance::1 months]] for the tolerance to be reduced to half and [[Time to zero tolerance::2-3 months]] to be back at baseline (in the absence of further consumption). MMDA presents cross-tolerance with [[Cross-tolerance::all [[dopamine]]rgic and [[serotonin|serotonergic]] [[stimulant]]s and entactogens]], meaning that after the consumption of MMDA all of these will have a reduced effect.


===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Stimulants|self=MDEA}}
{{DangerousInteractions/Stimulants|self=MMDA}}
{{DangerousInteractions/MAOI|nt=dopamine}}
{{DangerousInteractions/MAOI|nt=dopamine}}
*'''[[DangerousInteraction::Stimulants]]''' - The neurotoxic effects of MDEA may be increased when combined with other stimulants.
*'''[[DangerousInteraction::Stimulants]]''' - The neurotoxic effects of MMDA may be increased when combined with other stimulants.
*'''[[DangerousInteraction::Cocaine]]''' - This combination may increase strain on the heart.
*'''[[DangerousInteraction::Cocaine]]''' - This combination may increase strain on the heart.


====[[Serotonin syndrome]] risk====
====[[Serotonin syndrome]] risk====
{{DangerousInteractions/SerotoninSyndrome}}   
{{DangerousInteractions/SerotoninSyndrome}}   
There is an increased risk of serotonin syndrome when MDEA is taken with many antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, if MDEA is taken with SSRIs and SNRIs, the MDEA will be significantly less powerful or may have no distinguishable effects at all.
There is an increased risk of serotonin syndrome when MMDA is taken with many antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, if MMDA is taken with SSRIs and SNRIs, the MMDA will be significantly less powerful or may have no distinguishable effects at all.


==Legal issues==
==Legal status==
{{LegalStub}}
{{LegalStub}}
*'''UK:''' MDEA is a Class A drug.
*'''UK:''' MMDA is a Class A drug.{{citation needed}}
*'''USA:''' MDEA is a Schedule I drug.
*'''China:'''MMDA is a Schedule I controlled substance
 
==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
Line 154: Line 174:
*[[wikipedia:MMDA (drug)|MMDA (drug) (Wikipedia)]]
*[[wikipedia:MMDA (drug)|MMDA (drug) (Wikipedia)]]
*[https://isomerdesign.com/PiHKAL/explore.php?id=132 MMDA (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=132 MMDA (Isomer Design)]
*[https://go.drugbank.com/drugs/DB01442 MMDA (DrugBank)]
*[http://www.rollsafe.org/ RollSafe]
*[http://www.rollsafe.org/ RollSafe]


Retrieved from "https://psy.st/wiki/Talk:MMDA"
Return to "MMDA" page.